Patents by Inventor Peter Bruenker
Peter Bruenker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10087250Abstract: The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: October 3, 2013Date of Patent: October 2, 2018Assignee: Roche Glycart AGInventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umaña
-
Publication number: 20180273643Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: March 12, 2018Publication date: September 27, 2018Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane Neumann, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
-
Publication number: 20180142037Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: December 20, 2017Publication date: May 24, 2018Applicant: Roche Glycart AGInventors: Oliver AST, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Patent number: 9975958Abstract: The present invention pertains to a trimeric antigen binding molecule comprising three fusion polypeptides, each comprising at least one antigen binding moiety fused to a trimerization domain derived from human cartilage matrix protein. In addition, the present invention relates to polynucleotides encoding such trimeric antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the trimeric antigen binding molecules of the invention, and to methods of using these trimeric antigen binding molecules in the treatment of disease.Type: GrantFiled: November 6, 2015Date of Patent: May 22, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau-Richards, Ekkehard Moessner, Pablo Umana
-
Publication number: 20180086849Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: July 20, 2017Publication date: March 29, 2018Inventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Patent number: 9926379Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: April 1, 2014Date of Patent: March 27, 2018Assignee: ROCHE GLYCART AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
-
Publication number: 20170327579Abstract: A bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3?, characterized in comprising a common antibody light chain is provided. Such bispecific antibody can be used as a medicament in the treatment of plasma cell disorders like Multiple Myeloma.Type: ApplicationFiled: November 18, 2015Publication date: November 16, 2017Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, MARINA BACAC, PETER BRUENKER, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RAFT HOSSE, ADRIAN HUGENMATTER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, Samuel MOSER, Pablo UMANA
-
Publication number: 20170253670Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: May 19, 2017Publication date: September 7, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Christian Klein, Ekkehard Moessner, Ralf Hosse, Peter Bruenker, Pablo Umana, Christiane Neumann
-
Publication number: 20170247467Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moieties capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: September 29, 2016Publication date: August 31, 2017Applicant: Hoffmann-La Roche Inc.Inventors: MARIA AMANN, PETER BRUENKER, CHRISTINA CLAUS, CLAUDIA FERRARA KOLLER, SANDRA GRAU-RICHARDS, RALF HOSSE, CHRISTIAN KLEIN, VIKTOR LEVITSKI, SAMUEL MOSER, PABLO UMANA
-
Publication number: 20170198043Abstract: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: October 20, 2016Publication date: July 13, 2017Applicant: Roche Glycart AGInventors: Johannes Auer, Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Wolfgang Schaefer, Claudio Sustmann, Pablo Umana
-
Publication number: 20170145116Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.Type: ApplicationFiled: September 30, 2016Publication date: May 25, 2017Applicant: Hoffmann-La Roche Inc.Inventors: JOERG THOMAS REGULA, STEFAN SEEBER, WOLFGANG SCHAEFER, SABINE IMHOF-JUNG, MICHAEL MOLHOJ, MAXIMILIANE KOENIG, PETER BRUENKER, CHRISTIAN KLEIN
-
Publication number: 20170114141Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: September 29, 2016Publication date: April 27, 2017Applicant: Hoffmann-La Roche Inc.Inventors: MARIA AMANN, PETER BRUENKER, CHRISTINA CLAUS, CLAUDIA FERRARA KOLLER, SANDRA GRAU-RICHARDS, RALF HOSSE, CHRISTIAN KLEIN, VIKTOR LEVITSKI, PABLO UMANA
-
Publication number: 20170088631Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: ApplicationFiled: July 1, 2016Publication date: March 30, 2017Applicant: Roche Glycart AGInventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
-
Publication number: 20160340399Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: March 31, 2016Publication date: November 24, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
-
Publication number: 20160319036Abstract: The present invention relates to multispecific antibodies based on antibodies that share a common light chain. The multispecific antibodies include modified heavy chains comprising by domain exchange a common light chain variable domain VL; and two modified light chains comprising by domain exchange variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of said antibodies and their use.Type: ApplicationFiled: April 7, 2016Publication date: November 3, 2016Applicant: Hoffmann-La Roche Inc.Inventors: PETER BRUENKER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, WOLFGANG SCHAEFER
-
Patent number: 9481730Abstract: The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: September 27, 2010Date of Patent: November 1, 2016Assignee: Roche Glycart AGInventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau, Sylvia Herter, Christoph Lampert, Ekkehard Moessner, Pablo Umana, Inja Waldhauer
-
Patent number: 9447159Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: GrantFiled: April 26, 2012Date of Patent: September 20, 2016Assignee: Roche Glycart AGInventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
-
Publication number: 20160263240Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: ApplicationFiled: January 15, 2016Publication date: September 15, 2016Applicant: Roche Glycart AGInventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
-
Publication number: 20160208017Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: January 15, 2016Publication date: July 21, 2016Applicant: Roche Glycart AGInventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20160208019Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: November 20, 2015Publication date: July 21, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: Marina BACAC, Peter BRUENKER, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL